Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program

BACKGROUND: If SGLT2 inhibitors protect the kidneys by reducing albuminuria as hypothesized, people with type 2 diabetes mellitus (T2DM) with higher albuminuria should benefit more. METHODS: We conducted a post-hoc analysis of data from the CANagliflozin cardioVascular Assessment Study (CANVAS) Prog...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Am Soc Nephrol
Päätekijät: Neuen, Brendon L., Ohkuma, Toshiaki, Neal, Bruce, Matthews, David R., de Zeeuw, Dick, Mahaffey, Kenneth W., Fulcher, Greg, Li, Qiang, Jardine, Meg, Oh, Richard, Heerspink, Hiddo L., Perkovic, Vlado
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Nephrology 2019
Aiheet:
Clinical Research
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6830803/
https://ncbi.nlm.nih.gov/pubmed/31530577
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2019010064
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia